We are delighted to be working on this project along with our partner Solaris Biotech to manufacture Holiferm’s new pilot scale bioreactor. The design stage for the pilot bioreactor has now finished and construction phase has begun.
Solaris will be using their extensive expertise to construct this cutting edge bioreactor, having almost two decades of fermentation reactor design and construction experience under their belts.
This 450L working capacity reactor is planned to be operational and producing sophorolipid in early Q1 2021. It is estimated to be capable of producing 25 tonnes of product per annum and will enable Holiferm to provide sophorolipid samples for their partners’ pilot facilities to test in their formulations as well as allowing Holiferm to provide commercial quantities to smaller brands.
Tom Burdick said,